Target intelligence / Profile preview

Cytomegalovirus pp65 antigen-specific T cell (null)

Target
null
Molecular classification
Other (immune cell population)
01

Overview

Cytomegalovirus pp65 antigen-specific T cells are a subset of CD4+ and CD8+ T lymphocytes that recognize and respond to peptides derived from the pp65 (UL83) protein, the major structural protein in the viral tegument of HCMV. pp65 is involved in immune evasion and is highly immunogenic, making it the principal target for T cell-mediated immunity against CMV infection. These T cells clear infected cells through cytotoxic mechanisms and are critical for controlling viral replication and preventing CMV disease, especially in immunocompromised individuals (e.g., transplant recipients). Measurement of their frequency and function is important for clinical monitoring, and they are exploited in cellular immunotherapies and as biomarkers of antiviral immune competence. However, potential cross-reactivity of pp65-derived epitopes can theoretically contribute to autoimmune conditions via molecular mimicry.

Other names
CMV pp65-specific T cellHCMV pp65-specific T cellpp65 antigen-reactive T cell
02

Mechanism of action

Direct cytolytic killing of HCMV-infected cells via recognition of pp65 peptides presented on HLA class I/II molecules; Secretion of antiviral cytokines (e.g., IFN-γ, TNF-α, perforin)

03

Biological functions

Immune responseAntiviral defenseCytotoxic activity against infected cellsCytokine and chemokine secretion
04

Disease associations

Infection (cytomegalovirus)Autoimmunity (potential, e.g., lupus-like autoimmunity by molecular mimicry)
05

Safety considerations

Risk of graft-versus-host disease (GVHD) in cell therapy using allogeneic cellsPotential for inducing autoimmunity via molecular mimicry (dubious risk, mostly theoretical)Immunosuppression or viral escape in severely immunocompromised patients
06

Interacting drugs

Adoptive T cell therapies (autologous or allogeneic CMV pp65-specific T cells used therapeutically, especially in immunocompromised patients)

1 more in the full profile.

07

Biomarkers

CMV pp65-specific T cell frequency (used to monitor immunity and guide therapy in transplant patients)Polyfunctional cytokine response patterns (e.g., IFN-γ, TNF-α, perforin, CD107a, IL-2 production)

Beyond the preview

Go deeper on Cytomegalovirus pp65 antigen-specific T cell (null).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytomegalovirus pp65 antigen-specific T cell (null).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call